China-based WestVac Biopharma (Guangzhou) Co., Ltd., has claimed that with the support of the National Key R&D Program of China, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine (Sf9 cell) approved by NMPA, it has made significant progress on the development of the trivalent recombinant protein COVID-19 vaccine against the latest prevalent subvariants including XBB.1.5 and BA.5, which is one of the first trivalent recombinant protein vaccines targeting XBB.1.5 worldwide.

The company said that having taken advantage of the rapid response of the internationally advanced insect cell expression platform in recombinant protein vaccine production, WestVac Biopharma (Guangzhou) has constructed the vector within one month, and produced the trivalent recombinant protein vaccine of high purity and quality for human use. It is an entirely synthetic vaccine. At present, WestVac Biopharma is proactively engaged with the national authorities, and striving to meet the national approval requirements as soon as possible for the trivalent recombinant protein vaccine. The mission is to use WestVac BioPharma's power to aid in the fight against new variants of novel coronavirus!

WestVac Biopharma (Guangzhou) is a wholly-owned subsidiary of WestVac Biopharma Co., Ltd. located in the Innovative Vaccine Production Base in the Knowledge City of Guangzhou Economic Development Zone. With the production lines of a combined 5000L to be constructed soon for insect cell recombinant protein vaccine and nasal spray vaccine, it will have an annual production capacity of 500 million doses of vaccines.